Evidence map›Paper›PMID 41899938›Full record

ArticleEntropy (Basel, Switzerland)2026

Comparative Analysis of SARIMA, Prophet, and a Diagnostic Decomposition-Correction Hybrid for Long-Horizon Lottery Sales Forecasting.

Qian Cao, Zhenbang Sun, Huiyong Li

Abstract read
In one paragraph

Article in Entropy (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Qian CaoSchool of Computer and Artificial Intelligence, Beijing Technology and Business University, Beijing 100048, China.ORCID 0000-0002-2602-9472
Zhenbang SunSchool of Computer and Artificial Intelligence, Beijing Technology and Business University, Beijing 100048, China.
Huiyong LiSchool of Artificial Intelligence (Institute of Artificial Intelligence), Beihang University, Beijing 100191, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate forecasting of lottery sales is crucial for strategic planning in volatile consumer markets driven by trend shifts, multi-scale seasonality, and calendar effects. This study proposes a Diagnostic Decomposition-Correction Hybrid (DDC-Hybrid) framework integrating Prophet and SARIMA through a residual diagnostics and correction pipeline. Specifically, Prophet is employed to model long-term trend changes and interpretable holiday impacts, while SARIMA is subsequently used to correct the residual series, capturing short-range temporal dependence that remains statistically significant after decomposition. From an information-theoretic perspective, the framework can be viewed as a two-stage uncertainty reduction process, where decomposition extracts low-frequency informative components and residual correction harvests remaining predictive information. Using monthly lottery sales in China (2008-2025), we conduct a comprehensive evaluation of SARIMA, Prophet, and the proposed hybrid approach. The DDC-Hybrid demonstrates improved predictive accuracy, yielding the lowest error rates. Beyond predictive accuracy, we further examine varying holiday effects through statistical testing. We also find that lottery sales contain a pronounced quadrennial (48-month) seasonal cycle associated with mega-sport events, which improves long-horizon stability. The results suggest that the proposed diagnostic hybrid modeling approach enhances forecasting accuracy and provides practical insights for lottery sales management.

Indexed as

diagnostic hybrid modelinglong-cycle seasonalitylottery sales forecastingProphetSARIMA

Identifiers

PMID41899938
PMCPMC13025920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.